Back
Expedia Group Vs. Sarepta Therapeutics Industry Stock Comparison
Buy
93
EXPE
Expedia Group
Last Price:
186.42
Seasonality Move:
4.15%
Sell
49
SRPT
Sarepta Therapeutics
Last Price:
130.47
Seasonality Move:
14.88%
Buy
93
Expedia Group (EXPE)
is a Buy
Is Expedia Group a Buy, Sell or Hold?
- The current Expedia Group [EXPE] share price is $186.28. The Score for EXPE is 93, which is 86% above its historic median score of 50, and infers lower risk than normal.
- EXPE is currently trading in the 90-100% percentile range relative to its historical Stock Score levels.
- This Score is currently showing an extreme reading that indicates risk levels may be considerably lower than normal.
Sell
49
Sarepta Therapeutics (SRPT)
is a Sell
Is Sarepta Therapeutics a Buy, Sell or Hold?
- The current Sarepta Therapeutics [SRPT] share price is $130.50. The Score for SRPT is 49, which is 2% below its historic median score of 50, and infers higher risk than normal.
- SRPT is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
EXPE Stock Price Chart
What is Expedia Group's stock price today?
-
The Expedia Group share price today is $186.28
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and EXPE is experiencing buying pressure, which is a positive indicator for future bullish movement.
SRPT Stock Price Chart
What is Sarepta Therapeutics's stock price today?
-
The Sarepta Therapeutics share price today is $130.50
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and SRPT is experiencing buying pressure, which is a positive indicator for future bullish movement.
EXPE Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 7.31 | Buy |
| Relative Strength Index (14 RSI): | 71.49 | Buy |
| Chaikin Money Flow: | 834143 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (161.5 - 183.24) | Buy |
| Bollinger Bands (100): | (127.01 - 164.59) | Buy |
SRPT Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -2.3 | Sell |
| Relative Strength Index (14 RSI): | 64.59 | Buy |
| Chaikin Money Flow: | 3149400 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (111.02 - 128.88) | Buy |
| Bollinger Bands (100): | (119.18 - 142.3) | Sell |
EXPE Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 182.09 | Buy |
| 20-day SMA: | 175.76 | Buy |
| 50-day SMA: | 160.85 | Buy |
| 200-day SMA: | 136.63 | Buy |
| 8-day EMA: | 182.57 | Buy |
| 20-day EMA: | 176.27 | Buy |
| 50-day EMA: | 163.49 | Buy |
| 200-day EMA: | 141.4 | Buy |
SRPT Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 112.07 | Buy |
| 20-day SMA: | 117.27 | Buy |
| 50-day SMA: | 121.92 | Buy |
| 200-day SMA: | 129.99 | Buy |
| 8-day EMA: | 116.28 | Buy |
| 20-day EMA: | 117.14 | Buy |
| 50-day EMA: | 121.91 | Buy |
| 200-day EMA: | 125.98 | Buy |
Expedia Group Earnings Growth & EXPE Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.88 per share, a decrease next quarter of $0.00 per share, an increase this year of $2.10 per share, and an increase next year of $2.36 per share.
Sarepta Therapeutics Earnings Growth & SRPT Earnings Dates
- Analysts estimate an earnings increase this quarter of $2.87 per share, a decrease next quarter of $0.00 per share, an increase this year of $4.84 per share, and an increase next year of $8.76 per share.
Expedia Group Technical Analysis
| Nov 13 | Nov 14 | Nov 15 | Nov 18 | Nov 19 | Nov 20 | Nov 21 | Nov 22 | Nov 25 | Nov 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 13 | 14 | 15 | 18 | 19 | 20 | 21 | 22 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Sarepta Therapeutics Technical Analysis
| Nov 13 | Nov 14 | Nov 15 | Nov 18 | Nov 19 | Nov 20 | Nov 21 | Nov 22 | Nov 25 | Nov 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 13 | 14 | 15 | 18 | 19 | 20 | 21 | 22 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||